Recursion PharmaceuticalsRXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 500
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
139% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 46
51% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 47
10% more funds holding
Funds holding: 243 [Q1] → 267 (+24) [Q2]
7.82% more ownership
Funds ownership: 101.62% [Q1] → 109.43% (+7.82%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
10% less capital invested
Capital invested by funds: $2.11B [Q1] → $1.89B (-$221M) [Q2]
45% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $22.3M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Needham Gil Blum 40% 1-year accuracy 51 / 129 met price target | 65%upside $11 | Buy Maintained | 4 Sept 2024 |
Jefferies Dennis Ding 0% 1-year accuracy 0 / 3 met price target | 10%downside $6 | Hold Maintained | 3 Sept 2024 |
Leerink Partners Mani Foroohar 33% 1-year accuracy 5 / 15 met price target | 20%upside $8 | Market Perform Maintained | 3 Sept 2024 |
Needham Gil Blum 40% 1-year accuracy 51 / 129 met price target | 140%upside $16 | Buy Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 13 articles about RXRX published over the past 30 days